Japan Lifeline : Announces Changes in Board of Directors(126KB)
May 02, 2024 at 10:35 am
Share
May 1, 2024
To whom it may concern,
Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO (Code: 7575 TSE 1st Section)
Contact person: Takeyoshi Egawa, Vice President, Senior Manager of Business Administration Department (TEL. +81-3-6711-5200)
Japan Lifeline Announces Changes in Board of Directors
Japan Lifeline Co., Ltd. ("the Company") announced today that the Company has decided to make the following changes to the members of Board of Directors. This matter is to be officially decided at the Annual General Meeting of Shareholders, which is scheduled to be held on June 26, 2024, and at the subsequent Board of Directors' meeting and Audit and Supervisory Committee.
1. Newly Appointed Directors (Effective on June 26, 2024)
New position and title
Name
Old position and title
Vice President,
Senior Operating Officer,
Executive Manager of Arrhythmia
Takashi Ito
Executive Manager of Arrhythmia
Business Unit , Senior Manager of
Business Unit , Senior Manager of
Arrhythmia Sales Department
Arrhythmia Sales Department
Outside Director
Naoko Kawahara
Newly Appointed
(Lawyer, Tokyo Green Law Office)
Naoko Kawahara is a candidate for independent officer in accordance with the provisions of the Tokyo Stock Exchange. If the election of the candidate is approved at the Annual General Meeting of Shareholders to be held on June 26, 2024, the Company will submit the notification for her designation as an independent officer to the Exchange.
2. Resigning Directors (Effective on June 26, 2024) Yusuke Naiki, Outside Director
Attachments
Original Link
Original Document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on
01 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
02 May 2024 09:35:48 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
